Lidia Irene Staszewsky

List of Publications by Year
in descending order

75 papers	3,532 citations	186265 28 h-index	138484 58 g-index
77 all docs	77 docs citations	77 times ranked	5264 citing authors

#	Article	IF	Citations
1	Valsartan for Prevention of Recurrent Atrial Fibrillation. New England Journal of Medicine, 2009, 360, 1606-1617.	27.0	442
2	A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2046-2051.	7.1	231
3	Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. Journal of the American College of Cardiology, 2002, 40, 970-975.	2.8	228
4	Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. Journal of the American College of Cardiology, 2004, 43, 2022-2027.	2.8	206
5	Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. Journal of Molecular and Cellular Cardiology, 2004, 37, 959-968.	1.9	182
6	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-oneÂtrial. European Journal of Cancer, 2018, 94, 126-137.	2.8	163
7	Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood, 2010, 116, 5130-5139.	1.4	159
8	Cyclosporine A in ReperfusedÂMyocardialÂInfarction. Journal of the American College of Cardiology, 2016, 67, 365-374.	2.8	144
9	Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE Multicenter Trial. American Heart Journal, 1999, 138, 247-253.	2.7	136
10	Incremental Prognostic Value of Changes in B-Type Natriuretic Peptide in Heart Failure. American Journal of Medicine, 2006, 119, 70.e23-70.e30.	1.5	95
11	Cardiac mesoangioblasts are committed, self-renewable progenitors, associated with small vessels of juvenile mouse ventricle. Cell Death and Differentiation, 2008, 15, 1417-1428.	11.2	94
12	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. European Journal of Heart Failure, 2018, 20, 888-895.	7.1	93
13	Mesoangioblasts, Vessel-Associated Multipotent Stem Cells, Repair the Infarcted Heart by Multiple Cellular Mechanisms. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 692-697.	2.4	88
14	G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors. Clinical Cancer Research, 2008, 14, 7284-7291.	7.0	82
15	Clinical, Neurohormonal, and Inflammatory Markers and Overall Prognostic Role of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure: Data From the Val-HeFT Heart Failure Trial. Journal of Cardiac Failure, 2007, 13, 797-804.	1.7	80
16	Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-Atrial Fibrillation Trial. Journal of Internal Medicine, 2011, 269, 160-171.	6.0	63
17	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 2019, 21, 974-984.	7.1	52
18	Postresuscitation Treatment With Argon Improves Early Neurological Recovery in a Porcine Model of Cardiac Arrest. Shock, 2014, 41, 72-78.	2.1	49

#	Article	IF	Citations
19	Human cardiac mesoangioblasts isolated from hypertrophic cardiomyopathies are greatly reduced in proliferation and differentiation potency. Cardiovascular Research, 2009, 83, 707-716.	3.8	46
20	Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. Cardiology, 2017, 136, 128-137.	1.4	46
21	Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. Journal of Cardiovascular Medicine, 2006, 7, 29-38.	1.5	42
22	Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension. Cardiovascular Research, 2014, 104, 37-48.	3.8	42
23	Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISSI-AF trial. BMC Cardiovascular Disorders, 2013, 13, 28.	1.7	38
24	Early kynurenine pathway activation following cardiac arrest in rats, pigs, and humans. Resuscitation, 2013, 84, 1604-1610.	3.0	35
25	Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. American Heart Journal, 2013, 166, 935-940.e1.	2.7	35
26	LUCAS Versus Manual Chest Compression During AmbulanceÂTransport: A Hemodynamic Study in a Porcine ModelÂofÂCardiac Arrest. Journal of the American Heart Association, 2019, 8, e011189.	3.7	35
27	Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. Heart, 2010, 96, 1909-1914.	2.9	31
28	Cancer Incidence and Mortality According to Pre-Existing HeartÂFailure in a Community-Based Cohort. JACC: CardioOncology, 2022, 4, 98-109.	4.0	29
29	Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardicoâ€“Atrial Fibrillation (GISSI-AF) trial. American Heart Journal, 2011, 162, 382-389.	2.7	28
30	Systematic Review and Meta-Analysis: Renin-Angiotensin System Inhibitors in the Prevention of Atrial Fibrillation Recurrences. An Unfulfilled Hope. Cardiovascular Drugs and Therapy, 2012, 26, 47-54.	2.6	27
31	Diabetes mellitus as risk factor for atrial fibrillation hospitalization: Incidence and outcomes over nine years in a region of Northern Italy. Diabetes Research and Clinical Practice, 2015, 109, 476-484.	2.8	27
32	Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin. Journal of Clinical Medicine, 2020, 9, 1418.	2.4	27
33	Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in Heart Failure Trial (Val-HeFT). Journal of the American Society of Echocardiography, 2002, 15, 293-307.	2.8	26
34	Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: Findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)â€“3 trial. American Heart Journal, 2008, 155, 388-394.	2.7	26
35	Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. Journal of Cardiac Failure, 2004, 10, 433-441.	1.7	24
36	n-3PUFA and Holter-derived autonomic variables in patients with heart failure: Data from the Gruppo Italiano per lo Studio della Sopravvivenza nellâ€™Insufficienza Cardiaca (GISSI-HF) Holter substudy. Heart Rhythm, 2013, 10, 226-232.	0.7	23

#	Article	IF	Citations
37	Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009. European Journal of Heart Failure, 2016, 18, 840-848.	7.1	23
38	Duration of Untreated Cardiac Arrest and Clinical Relevance of Animal Experiments: The Relationship Between the â€œNo-Flowâ€•Duration and the Severity of Post-Cardiac Arrest Syndrome in a Porcine Model. Shock, 2018, 49, 205-212.	2.1	23
39	Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure. Pharmacological Research, 2013, 73, 35-43.	7.1	22
40	Incremental Value of Left Ventricular Systolic and Diastolic Function to Determine Outcome in Patients with Acute STâ€Segment Elevation Myocardial Infarction: The Echocardiographic Substudy of the OASISâ€6 Trial. Echocardiography, 2014, 31, 569-578.	0.9	22
41	Histone Deacetylase Inhibition Enhances Self Renewal and Cardioprotection by Human Cord Blood-Derived CD34+ Cells. PLoS ONE, 2011, 6, e22158.	2.5	21
42	Relationship between post-cardiac arrest myocardial oxidative stress and myocardial dysfunction in the rat. Journal of Biomedical Science, 2014, 21, 70.	7.0	18
43	Circulating biomarkers and cardiac function over 3Âyears after chemotherapy with anthracyclines: the ICOSâ€ONE trial. ESC Heart Failure, 2020, 7, 1452-1466.	3.1	16
44	A novel echocardiographic method closely agrees with cardiac magnetic resonance in the assessment of left ventricular function in infarcted mice. Scientific Reports, 2019, 9, 3580.	3.3	15
45	Ventilation With Argon Improves Survival With Good Neurological Recovery After Prolonged Untreated Cardiac Arrest in Pigs. Journal of the American Heart Association, 2020, 9, e016494.	3.7	15
46	Left Atrial Remodeling and Response to Valsartan in the Prevention of Recurrent Atrial Fibrillation. Circulation: Cardiovascular Imaging, 2011, 4, 721-728.	2.6	14
47	Effect of mild hypercapnia on outcome and histological injury in a porcine post cardiac arrest model. Resuscitation, 2019, 135, 110-117.	3.0	14
48	Signs and symptoms in chronic heart failure: Relevance of clinical trial results to point of care-data from Val-HeFT. European Journal of Heart Failure, 2006, 8, 502-508.	7.1	12
49	Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation. BMC Cardiovascular Disorders, 2021, 21, 553.	1.7	12
50	What is the atrium trying to tell us?. European Heart Journal, 2013, 34, 255-257.	2.2	11
51	Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial. Cardiovascular Drugs and Therapy, 2015, 29, 551-561.	2.6	11
52	Monocrotaline-induced pulmonary arterial hypertension: Time-course of injury and comparative evaluation of macitentan and Y-27632, a Rho kinase inhibitor. European Journal of Pharmacology, 2019, 865, 172777.	3.5	11
53	Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2012, 26, 131-143.	2.6	10
54	Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest. Heart Rhythm, 2014, 11, 1641-1647.	0.7	9

#	Article	IF	Citations
55	IGFBP7 and GDF-15, but not P1NP, are associated with cardiac alterations and 10-year outcome in an elderly community-based study. BMC Cardiovascular Disorders, 2021, 21, 328.	1.7	9
56	Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment: in vitro and in vivo studies. Cytotherapy, 2011, 13, 1140-1152.	0.7	8
57	A mouse model for spatial and temporal expression of HGF in the heart. Transgenic Research, 2011, 20, 1203-1216.	2.4	8
58	Neurohormonal modulation in heart failure of ischemic etiology: Correlates with left ventricular remodeling. Current Heart Failure Reports, 2006, 3, 157-163.	3.3	6
59	Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook. Expert Review of Cardiovascular Therapy, 2016, 14, 703-711.	1.5	6
60	Semaglutide and effective weight control. Lancet, The, 2021, 397, 942-943.	13.7	6
61	Esmolol during cardiopulmonary resuscitation reduces neurological injury in a porcine model of cardiac arrest. Scientific Reports, 2021, 11, 10635.	3.3	6
62	Screening for unknown atrial fibrillation in older people: a feasibility study in community pharmacies. European Geriatric Medicine, 2018, 9, 113-115.	2.8	5
63	Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia. Cancers, 2020, 12, 2312.	3.7	5
64	Valsartan for the treatment of heart failure. Expert Opinion on Pharmacotherapy, 2004, 5, 181-193.	1.8	4
65	Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study. Diabetes Research and Clinical Practice, 2018, 146, 172-179.	2.8	3
66	Adrenomedullin, a circulating biomarker of congestion: in search of evidence. European Journal of Heart Failure, 2019, 21, 1062-1063.	7.1	2
67	Searching for Preclinical Models of Acute Decompensated Heart Failure: a Concise Narrative Overview and a Novel Swine Model. Cardiovascular Drugs and Therapy, 2022, 36, 727-738.	2.6	2
68	Brain Kynurenine Pathway and Functional Outcome of Rats Resuscitated From Cardiac Arrest. Journal of the American Heart Association, 2021, 10, e021071.	3.7	2
69	Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications. BMJ Open Diabetes Research and Care, 2022, 10, e002708.	2.8	2
70	Risk stratification according to insulin type: reply. European Journal of Heart Failure, 2018, 20, 1498-1498.	7.1	1
71	Primary pulmonary arterial hypertension: Protocol to assess comprehensively in the rat the response to pharmacologic treatments. MethodsX, 2020, 7, 100771.	1.6	1
72	Cardiovascular mortality and morbidity burden in successive and age pre-stratified caseâ€“control cohorts of breast cancer women. A population-based study. Breast Cancer Research and Treatment, 2020, 183, 177-188.	2.5	1

#	Article	IF	Citations
73	Ventilation with the noble gas argon in an in vivo model of idiopathic pulmonary arterial hypertension in rats. Medical Gas Research, 2021, 11, 124.	2.3	1
74	Prevention of Myocardial Remodeling by Chronic INaL Blockade in Pulmonary Hypertension. Biophysical Journal, 2012, 102, 340a.	0.5	0
75	Relationship between plasma high-sensitive cardiac Troponin T and infarct size in a porcine model of acute myocardial infarction and cardiac arrest and resuscitation. Resuscitation, 2014, 85, S13-S14.	3.0	0